Dexpramipexole (dihydrochloride)

Modify Date: 2024-01-02 14:08:56

Dexpramipexole (dihydrochloride) Structure
Dexpramipexole (dihydrochloride) structure
Common Name Dexpramipexole (dihydrochloride)
CAS Number 104632-27-1 Molecular Weight 284.24900
Density N/A Boiling Point N/A
Molecular Formula C10H19Cl2N3S Melting Point N/A
MSDS Chinese USA Flash Point N/A
Symbol GHS07
GHS07
Signal Word Warning

 Use of Dexpramipexole (dihydrochloride)


Dexpramipexole 2Hcl(KNS-760704), also known as R-(+)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist. IC50 Value:Target: Dopamine ReceptorDexpramipexole has been found to have neuroprotective effects and is being investigated for treatment of amyotrophic lateral sclerosis (ALS). Dexpramipexole reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, Dexpramipexole has much lower dopamine agonist activity.

 Names

Name (6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine,dihydrochloride
Synonym More Synonyms

 Dexpramipexole (dihydrochloride) Biological Activity

Description Dexpramipexole 2Hcl(KNS-760704), also known as R-(+)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist. IC50 Value:Target: Dopamine ReceptorDexpramipexole has been found to have neuroprotective effects and is being investigated for treatment of amyotrophic lateral sclerosis (ALS). Dexpramipexole reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, Dexpramipexole has much lower dopamine agonist activity.
Related Catalog
References

[1]. Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler

[2]. Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 2012 Mar 29;1446:1-11.

[3]. Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20;17(12):1652-6.

[4]. Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol. 2011 Aug;51(8):1177-85.

[5]. Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Dec;13(12):911-20.

 Chemical & Physical Properties

Molecular Formula C10H19Cl2N3S
Molecular Weight 284.24900
Exact Mass 283.06800
PSA 79.91000
LogP 3.50720
Appearance of Characters white to beige
Storage condition ?20°C
Water Solubility H2O: >15mg/mL

 Safety Information

Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H315-H319-H335
Precautionary Statements P261-P305 + P351 + P338
Hazard Codes Xi
Risk Phrases 36/37/38
Safety Phrases 26
RIDADR NONH for all modes of transport

 Synonyms

(R)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine dihydrochloride
(+)-2-amino-6-(propylamino)tetrahydrobenzothiazole dihydrochloride
(+)-Pramipexole dihydrochloride
(+)-2-amino-4,5,6,7-tetrahydro-6-L-propylaminobenzathiazole dihydrochloride
SND 919CL2x
2,6-Benzothiazolediamine,4,5,6,7-tetrahydro-N6-propyl-,dihydrochloride,(R)
CS-1195
Bio-0080
UNII-I9038PKO43
(-)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole dihydrochloride
Dexpramipexole (dihydrochloride)